New cocktail aims to make inoperable liver metastases removable

NCT ID NCT07649473

Not yet recruiting Disease control Sponsor: Fujian Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding an experimental immunotherapy drug (QL1706) to standard chemotherapy and radiation can shrink liver tumors from colon cancer enough to allow surgery. About 30 adults with colon cancer that has spread only to the liver will receive the combination before planned surgery. The goal is to see if more patients can achieve complete removal of all visible cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QL1706 (Iparomlimab/Tuvonralimab) combined with CAPOX chemotherapy and bevacizumab, plus stereotactic body radiation therapy (SBRT)
What this could lead to: If successful, this approach could help more patients with colon cancer that has spread to the liver become eligible for surgery, potentially improving long-term outcomes.
What could go wrong: This is a small, early-phase study with only 30 participants and no comparison group. The combination therapy may cause significant side effects, and it is not yet known if it will improve survival or cure rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLON ADENOCARCINOMA WITH SYNCHRONOUS LIVER-ONLY METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colon adenocarcinoma colon carcinoma colonic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLON CANCER SYNCHRONOUS LIVER METASTASES

Contacts and locations

Locations

The First Affiliated Hospital of Fujian Medical University

Fuzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.